PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620720914490
Abstract: Recent results of randomized phase III studies of FDG-PET-adapted therapy for advanced Hodgkin lymphoma (HL) have clearly demonstrated benefit to alteration of treatment according to interim response, in particular regarding reducing toxicity while maintaining efficacy.… read more here.
Keywords: advanced hodgkin; therapy advanced; pet adapted; hodgkin lymphoma ... See more keywords
Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-212005
Abstract: Background: Brentuximab vedotin (Bv), Nivolumab (N) and Pembrolizumab (P) have revolutionized the management of advanced stage classical Hodgkin Lymphoma (AS cHL). Significant improvements in both safety and efficacy have been observed with the Echelon-1 (E1)… read more here.
Keywords: pembrolizumab; hodgkin; pet adapted; safety ... See more keywords
Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma.
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood.2019000719
Abstract: Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on S0816 (NCT00822120). Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving… read more here.
Keywords: pfs; hodgkin lymphoma; pet2; year ... See more keywords